Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Caldwell

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
Journal of Hepatology|January 23, 2021
A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCAJörn M Schattenberg, Albert Pares, Kris V Kowdley, et al.
Transfusion|March 30, 2010
Evidence-based practice guidelines for plasma transfusionJohn D Roback, Stephen Caldwell, Jeff Carson, et al.
Journal of Hepatology|August 26, 2018
The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment optionsZobair Younossi, Maria Stepanova, Arun J Sanyal, et al.
Clinical and Translational Gastroenterology|July 8, 2024
Cilofexor in Patients With Compensated Cirrhosis Due to Primary Sclerosing Cholangitis: An Open-Label Phase 1B StudyCynthia Levy, Stephen Caldwell, Parvez Mantry, et al.
Hepatology (Baltimore, Md.)|January 21, 2019
The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing CholangitisMichael Trauner, Aliya Gulamhusein, Bilal Hameed, et al.
Hepatology (Baltimore, Md.)|August 29, 2018
Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the DiseaseAndrew J Muir, Cynthia Levy, Harry L A Janssen, et al.
Hepatology (Baltimore, Md.)|April 18, 2019
The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab TrialsArun J Sanyal, Stephen A Harrison, Vlad Ratziu, et al.
Biochemical Pharmacology|May 26, 2007
Modulation of hepatic microsomal triglyceride transfer protein (MTP) induced by S-nitroso-N-acetylcysteine in ob/ob miceClaudia P M S Oliveira, Venâncio A F Alves, Vicência M R Lima, et al.
Gastroenterology|July 11, 2018
Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic SteatohepatitisStephen A Harrison, Manal F Abdelmalek, Stephen Caldwell, et al.
The Lancet. Gastroenterology & Hepatology|October 31, 2025
Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): a randomised, double-blind, multicentre, placebo-controlled, phase 3 trialMichael Trauner, Cynthia Levy, Atsushi Tanaka, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Journal of Hepatology|January 23, 2021
A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCAJörn M Schattenberg, Albert Pares, Kris V Kowdley, et al.
Transfusion|March 30, 2010
Evidence-based practice guidelines for plasma transfusionJohn D Roback, Stephen Caldwell, Jeff Carson, et al.
Journal of Hepatology|August 26, 2018
The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment optionsZobair Younossi, Maria Stepanova, Arun J Sanyal, et al.
Clinical and Translational Gastroenterology|July 8, 2024
Cilofexor in Patients With Compensated Cirrhosis Due to Primary Sclerosing Cholangitis: An Open-Label Phase 1B StudyCynthia Levy, Stephen Caldwell, Parvez Mantry, et al.
Hepatology (Baltimore, Md.)|January 21, 2019
The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing CholangitisMichael Trauner, Aliya Gulamhusein, Bilal Hameed, et al.
Hepatology (Baltimore, Md.)|August 29, 2018
Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the DiseaseAndrew J Muir, Cynthia Levy, Harry L A Janssen, et al.
Hepatology (Baltimore, Md.)|April 18, 2019
The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab TrialsArun J Sanyal, Stephen A Harrison, Vlad Ratziu, et al.
Biochemical Pharmacology|May 26, 2007
Modulation of hepatic microsomal triglyceride transfer protein (MTP) induced by S-nitroso-N-acetylcysteine in ob/ob miceClaudia P M S Oliveira, Venâncio A F Alves, Vicência M R Lima, et al.
Gastroenterology|July 11, 2018
Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic SteatohepatitisStephen A Harrison, Manal F Abdelmalek, Stephen Caldwell, et al.
The Lancet. Gastroenterology & Hepatology|October 31, 2025
Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): a randomised, double-blind, multicentre, placebo-controlled, phase 3 trialMichael Trauner, Cynthia Levy, Atsushi Tanaka, et al.
Pageof 6